The specialist physician’s approach to rheumatoid arthritis in South Africa

키워드

참고문헌 (91)

1. Still L, "Health Care in South Africa" (2014), Profile Media
2. Fellingham SA, "Mseleni joint disease: background and prevalence", S Afr Med J, 47, pp.2173~2180 (1973)
3. Tikly M, "The scourge of HIV infection in sub-Saharan Africa: a rheumatological perspective", J Rheumatol, 38, pp.973~974 (2011)
4. Asherson RA, "The catastrophic antiphospholipid syndrome", J Rheumatol, 19, pp.508~512 (1992)
5. McGill P, "Rheumatoid arthritis in sub-Saharan Africa", Ann Rheum Dis, 50, pp.965~966 (1991)
6. Mody GM, "Rheumatoid arthritis in blacks in South Africa", Ann Rheum Dis, 48, pp.69~72 (1989)
7. Okada H, "The ‘hygiene hypothesis’for autoimmune and allergic diseases: an up-date", Clin Exp Immunol, 160, pp.1~9 (2010)
8. Arnett FC, "The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis", Arthritis Rheum, 31, pp.315~324 (1998)
9. Singh JA, "Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis", Arthritis Care Res, 64, pp.625~639 (2012)
10. Aletaha D, "Rheumatoid arthritis classification criteria: an American College of Rheumatology", European League Against Rheumatism collaborative initiative, 2010, pp.62, 2569~2581
11. Hodkinson B, "South African recommendations for the management of rheumatoid arthritis: an algorithm for the standard of care in 2013", S Afr Med J, 103(8 Pt 2), pp.576~585 (2013)
12. Wolfe F, "50 Years of antirheumatic therapy: the prognosis of rheumatoid arthritis", J Rheumatol Suppl, 22, pp.24~32 (1990)
13. Anderson JJ, "Factors predicting response to treatment in rheumatoid arthritis:the importance of disease duration", Arthritis Rheum, 43, pp.22~29 (2000)
14. Hulsmans HM, "The course of radiologic damage during the first six years of rheumatoid arthritis", Arthritis Rheum, 43, pp.1927~1940 (2000)
15. O’Dell JR, "How is it best to treat early rheumatoid arthritis patients?", Best Pract Res Clin Rheumatol, 15, pp.125~137 (2001)
16. Nell VP, "Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis", Rheumatology, 43, pp.906~914 (2004)
17. "Have you got the S factor? 2013" (2015)[URL]
18. Beattie KA, "Screening for signs and symptoms of rheumatoid arthritis by family physicians and nurse practitioners using the gait, arms, legs, and spine musculoskeletal examination", Arthritis Care Res, 64, pp.1923~1927 (2012)
19. Wiesinger T, "Compression test (Gaenslen’s squeeze test) positivity, joint tenderness, and disease activity in patients with rheumatoid arthritis", Arthritis Care Res, 65, pp.653~657 (2013)
20. van der Heijde DM, "Disease activity score", Ann Rheum Dis, 51, pp.140~ (1992)
21. Aletaha D, "The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis", Clin Exp Rheumatol, 23(5 Suppl 39), pp.S100~S108 (2005)
22. Aletaha D, "Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score", Arthritis Res Ther, 7, pp.R796~R806 (2005)
23. Smolen JS, "The assessment of disease activity in rheumatoid arthritis", Clin Exp Rheumatol, 28(3Suppl 59), pp.S18~S27 (2010)
24. Felson DT, "American College of Rheumatology: preliminary definition of improvement in rheumatoid arthritis", Arthritis Rheum, 38, pp.727~735 (1995)
25. Knevel R, "Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis", Ann Rheum Dis, 69, pp.987~994 (2010)
26. Kirwan JR, "Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis", Br J Rheumatol, 25, pp.206~209 (1986)
27. Hazes JM, "Determinants of physical function in rheumatoid arthritis: association with the disease process", Rheumatology, 42(Suppl 2), pp.ii17~ii21 (2003)
28. Scott DL, "Joint damage and disability in rheumatoid arthritis: an updated systematic review", Clin Exp Rheumatol, 21(5 Suppl 31), pp.S20~S27 (2003)
29. Gossec L, "Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study", Ann Rheum Dis, 63, pp.675~680 (2004)
30. Wakefield RJ, "The role of ultrasonography and magnetic resonance imaging in early rheumatoid arthritis", Clin Exp Rheumatol, 21(5 Suppl 31), pp.S42~S49 (2003)
31. Hammer HB, "Advances in imaging", Curr Opin Rheumatol, 24, pp.299~305 (2012)
32. Yazici Y, "Monitoring methotrexate hepatic toxicity in rheumatoid arthritis: is it time to update the guidelines?", J Rheumatol, 29, pp.1586~1589 (2002)
33. Salliot C, "Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis:a systematic literature research", Ann Rheum Dis, 68, pp.1100~1104 (2009)
34. Kalla AA, "Rheumatoid arthritis: clinical guideline 2003", S Afr Med J, 93(12 Pt 2), pp.991~1012 (2003)
35. Kirwan JR, "Effects of glucocorticoids on radiological progression in rheumatoid arthritis", Cochrane Database Syst Rev, (1), pp.CD006356~ (2007)
36. Mouterde G, "Ruyssen-Witrand A, et al. Indications of glucocorticoids in early arthritis and rheumatoid arthritis: recommendations for clinical practice based on data from the literature and expert opinion", Joint Bone Spine, 77, pp.597~603 (2010)
37. Gorter SL, "Current evidence for the management of rheumatoid arthritis with glucocorticoids:a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis", Ann Rheum Dis, 69, pp.1010~1014 (2010)
38. Horton S, "Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations", Drug Healthc Patient Saf, 2, pp.101~119 (2010)
39. Smolen JS, "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs", Ann Rheum Dis, 69, pp.964~975 (2010)
40. Hodkinson B, "Response to traditional disease-modifying anti-rheumatic drugs in indigent South Africans with early rheumatoid arthritis", Clin Rheumatol, 31, pp.613~619 (2012)
41. Khanna D, "Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort", Arthritis Rheum, 57, pp.440~447 (2007)
42. Isaacs JD, "The need for personalised medicine for rheumatoid arthritis", Ann Rheum Dis, 70, pp.4~7 (2011)
43. Reynolds A, "When is switching warranted among biologic therapies in rheumatoid arthritis?", Expert Rev Pharmacoecon Outcomes Res, 12, pp.319~333 (2012)
44. Chan FK, "Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents", Am J Gastroenterol, 103, pp.2908~2918 (2008)
45. McGettigan P, "Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2", JAMA, 296, pp.1633~1644 (2006)
46. Hill J, "Rheumatology nurse specialists: do we need them?", Rheumatology, 46, pp.379~381 (2007)
47. Baka Z, "Rheumatoid arthritis and smoking: putting the pieces together", Arthritis Res Ther, 11, pp.238~ (2009)
48. Skytta ET, "Fewer and older patients with rheumatoid arthritis need total knee replacement", Scand J Rheumatol, 41, pp.345~349 (2012)
49. Baronnet L, "Incidence of tuberculosis in patients with rheumatoid arthritis: a systematic literature review", Joint Bone Spine, 78, pp.279~284 (2011)
50. Gardam MA, "Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management", Lancet Infect Dis, 3, pp.148~155 (2003)
51. Winthrop KL, "Tuberculosis associated with therapy against tumor necrosis factor alpha", Arthritis Rheum, 52, pp.2968~2974 (2005)
52. Carmona L, "Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists", Arthritis Rheum, 52, pp.1766~1772 (2005)
53. Dixon WG, "Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)", Ann Rheum Dis, 69, pp.522~528 (2010)
54. Jasmer RM, "Clinical practice: latent tuberculosis infection", N Engl J Med, 347, pp.1860~1866 (2002)
55. Menzies R, "Effect of bacille Calmette-Guérin vaccination on tuberculin reactivity", Am Rev Respir Dis, 145, pp.621~625 (1992)
56. Pouchot J, "Reliability of tuberculin skin test measurement", Ann Intern Med, 126, pp.210~214 (1997)
57. Dheda K, "Utility of the antigen-specific interferon-gamma assay for the management of tuberculosis", Curr Opin Pulm Med, 11, pp.195~202 (2005)
58. Pooran A, "Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis", BMC Pulm Med, 10, pp.7~ (2010)
59. Denkinger CM, "Guidelines on interferon-γ release assays for tuberculosis infection: concordance, discordance or confusion?", Clin Microbiol Infect, 17, pp.806~814 (2011)
60. Martinson NA, "New regimens to prevent tuberculosis in adults with HIV infection", N Engl J Med, 365, pp.11~20 (2011)
61. "South African tuberculosis profile 2011" (2015)[URL]
62. "Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement", Am J Respir Crit Care Med, 161(4Pt 2), pp.S221~S247 (2000)
63. Tam LS, "Risk of tuberculosis in patients with rheumatoid arthritis in Hong Kong: the role of TNF blockers in an area of high tuberculosis burden", Clin Exp Rheumatol, 28, pp.679~685 (2010)
64. Tubach F, "Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry", Arthritis Rheum, 60, pp.1884~1894 (2009)
65. Wallis RS, "Biologics and infections: lessons from tumor necrosis factor blocking agents", Infect Dis Clin North Am, 25, pp.895~910 (2011)
66. Nam JL, "Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs:a systematic literature review informing the EULAR recommendations for the management of RA", Ann Rheum Dis, 69, pp.976~986 (2010)
67. Handa R, "Guidelines for tuberculosis prophylaxis during anti-tumour necrosis factor-α treatment: Indian Rheumatology Association", APLAR J Rheumatol, 9, pp.181~183 (2006)
68. El Maghraoui A, "Recommandations de la Societe Marocaine de Rhumatologie pour la prise en charge de la polyarthrite rhumatoide", Rev Maroc Rhumatol, 2-3, pp.45~61 (2007)
69. Xanthouli P, "Rituximab (RTX) as an alternative to TNF-alpha antagonists in patients with rheumatoid arthritis and high risk of severe infections: a systematic analysis of the experience in one center", Open Rheumatol J, 6, pp.286~289 (2012)
70. Rehle TM, "A decline in new HIV infections in South Africa: estimating HIV incidence from three national HIV surveys in 2002, 2005 and 2008", PLoS One, 5, pp.e11094~ (2010)
71. Mody GM, "Articular manifestations of human immunodeficiency virus infection", Best Pract Res Clin Rheumatol, 17, pp.265~287 (2003)
72. McLean-Tooke A, "Methotrexate, rheumatoid arthritis and infection risk:what is the evidence?", Rheumatology, 48, pp.867~871 (2009)
73. Paton NI, "Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks", HIV Med, 6, pp.13~20 (2005)
74. Ndakotsu MA, "Relation between erythrocyte sedimentation rate, clinical and immune status in HIV-infected patients", Niger J Med, 18, pp.208~210 (2009)
75. Vigano M, "Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management", Expert Opin Biol Ther, 12, pp.193~207 (2012)
76. Ferri C, "The A, B, Cs of viral hepatitis in the biologic era", Curr Opin Rheumatol, 22, pp.443~450 (2010)
77. Peters MJ, "Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study", Arthritis Rheum, 61, pp.1571~1579 (2009)
78. Peters MJ, "EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis", Ann Rheum Dis, 69, pp.325~331 (2010)
79. Klug E, "South African dyslipidaemia guideline consensus statement", S Afr Med J, 102(3 Pt 2), pp.178~187 (2012)
80. Gabriel SE, "Risk factors for cardiovascular disease in rheumatoid arthritis", Curr Opin Rheumatol, 24, pp.171~176 (2012)
81. Westlake SL, "The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review", Rheumatology, 49, pp.295~307 (2010)
82. Vis M, "Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis", Ann Rheum Dis, 65, pp.1495~1499 (2006)
83. van Staa TP, "The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis", Osteoporos Int, 13, pp.777~787 (2002)
84. Grossman JM, "American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis", Arthritis Care Res, 62, pp.1515~1526 (2010)
85. Baecklund E, "Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis", Arthritis Rheum, 54, pp.692~701 (2006)
86. Askling J, "Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?", Arthritis Rheum, 60, pp.3180~3189 (2009)
87. Buch MH, "Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis", Ann Rheum Dis, 70, pp.909~920 (2011)
88. Raaschou P, "Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents", Arthritis Rheum, 63, pp.1812~1822 (2011)
89. Boulman N, "Anti-tumor necrosis factor treatment and pregnancy: the way is open", Clin Exp Rheumatol, 30, pp.453~ (2012)
90. Visser K, "Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative", Ann Rheum Dis, 68, pp.1086~1093 (2009)
91. Roy S, "Number needed to treat for biologic therapies in patients with active rheumatoid arthritis despite methotrexate:a mixed treatment comparison meta-analysis", Ann Rheum Dis, 70(Suppl 3), pp.432~ (2011)

관련 논문AI추천